

p.02

YO Track

Find out what's in store for younger oncologists at ESMO 2016

p.02

ESMO/ASCO Global Curriculum

The 2016 edition includes updated sections and brand new chapters

p.03

ESMO Focus Talks

Learn more about this new initiative and what ESMO can do for you

p.07

ESMO awards

ESMO recognises the outstanding contributions made by our awardees

Today's Top Picks

COPENHAGEN 2016



FRIDAY 7 OCTOBER, 2016



FROM DISEASE TREATMENT TO PATIENT CARE

DAILY REPORTER

Welcome to ESMO 2016, the leading oncology event in Europe

I am incredibly proud to welcome you all to ESMO 2016, ESMO's first annual congress.



Hello from the Daily Reporter team



Giuseppe Curigliano: Editor-in-Chief of the ESMO 2016 Daily Reporter
European Institute of Oncology, Milan, Italy

ESMO 2016 here in Copenhagen promises to be a truly impressive Congress, with a scientific programme that blends cutting-edge science with evolving clinical practice.

Over the next five days, we at the *Daily Reporter* will help you to navigate this exciting and busy Congress. As well as bringing you reports on the latest ground-breaking data, we will be turning the spotlight on sessions and topics across multiple disciplines.

Helpful Congress Information

Abstracts

All accepted abstracts are published online as a supplement of *Annals of Oncology*, ESMO's flagship journal.

ePosters area


Several large plasma touch screens allow attendees to search and view ESMO 2016 posters electronically. The ePoster area is located in the North Hall, near the traditional posters and is open from Saturday 8 to Monday 10 October.

Exhibition

The exhibition is open from Friday 7 October to Monday 10 October.

Opening hours:

Friday 7 October, 2016	13.00 – 17.00
Saturday 8 October, 2016	10.00 – 17.00
Sunday 9 October, 2016	10.00 – 17.00
Monday 10 October, 2016	10.00 – 16.30



Fortunato Ciardiello: ESMO President

This international congress expects to play host to more than 19,000 participants from over 130 countries, including oncology professionals from a variety of fields and related disciplines, policy makers and patient advocates.

The tagline of this year's congress, 'From disease treatment to patient care', is intended to capture and integrate clinical research with patient needs, and reinforces our commitment to bring the best possible treatments to all patients with cancer, regardless of nationality and economic obstacles. The varied programme we have planned for you over the coming days has something for everyone. ESMO's commitment to facilitating and encouraging education and research extends to its support of its younger members and an

independent track is fully dedicated to young oncologists. The role of women and their career development in oncology is also actively encouraged and recognised by ESMO.

We are amazed by the number of high-quality abstracts we have received across all disciplines. The fact that so many researchers

"ESMO 2016 is the best congress for all oncology stakeholders."

have chosen ESMO 2016 as the place to present their ground-breaking data highlights the importance with which the congress is viewed by the oncology community. ESMO is unique in having a highly flexible programme, which can accommodate the large number of important studies submitted and give them prominent exposure in key sessions.

Communication is key to improving progress in research and it is my belief that ESMO 2016 offers a wealth of opportunities for delegates to discuss findings with experts and colleagues and to make new contacts. At ESMO, we like to think that the congress is the place where ESMO meets the community and members meet their leaders, and as an avid supporter of this philosophy, I will be only too happy to chat with delegates in the ESMO Members' Lounge.

It just remains for me to urge you to participate, learn and enjoy!

"Get your copy of the ESMO 2016 Daily Reporter hot off the press each morning from stands around the Congress centre."

The ESMO 2016 *Daily Reporter* is the official news source for the ESMO annual congress, providing expert perspectives on hot topics and session highlights, with live reporting and critical insights on data. The content includes physician-authored expert editorials on current clinical issues in oncology, interviews with congress attendees, and recaps of key sessions and presentations. Our stellar Editorial Board—comprising me and Associate Editors Evandro de Azambuja, Markus Joerger, Floriana Morgillo and Stefan Zimmermann—draws on experience across therapeutic areas to ensure the wide appeal of the paper's content.

ESMO 2016 Wi-Fi access



Wi-Fi access is free to the ESMO Congress delegates.

Connection information:
Network name (SSID): ESMO2016

No authentication is needed once selected

ESMO 2016 Patient Advocacy Track—educating patient advocates



Bettina Ryll: ESMO 2016 Patient Advocacy Track Chair

How important is the Patient Advocacy Track?

Patient advocates act as communicators and connectors between patients and other stakeholder groups. Successful interaction relies on advocates' expertise, making education and training our top priorities. Navigating today's healthcare systems is complex and requires both medical knowledge and insight into the operating and constraints of the system itself. ESMO 2016 is a fantastic opportunity to provide both!

Can you outline the programme content?

The ESMO Patient Advocacy Working Group (PAWG) identified topics of general relevance in oncology (like disparities in cancer care, adverse event reporting, and cancer and pregnancy) and special emphasis is given to how best to leverage the potential of our patient networks to produce tangible outcomes.

As timely access to innovative medicines remains a challenge for European cancer patients, our special sessions focus on two different aspects of access: Medicines Adaptive Pathways to Patients (MAPPS), a new way to approve innovative medicines in Europe, and market entry agreements, which are financial schemes that facilitate access.

What do you hope the track will achieve?

In times of increasing financial constraints, understanding the economic and structural constraints of our healthcare systems is essential for both patient advocates and oncologists to ensure best outcomes for European cancer patients.

Our new concept therefore unblocks the advocacy track from the scientific tracks, allowing advocates and oncologists to profit from both. We have planned for sufficient discussion time to provide a platform for exchange and alignment that will hopefully continue after the end of the conference!

ESMO 2016 poster USB



Get the ESMO 2016 electronic posters on a handy USB memory stick and browse them at your leisure.

You will find the voucher in your delegate bag: simply take it to the ESMO Booth in the Society Village.

The Young Oncologists Track: Inspiring oncology leaders of the future

ESMO 2016 marks my first year as Chair of the ESMO Young Oncologists (YO) Committee and I would like to give special thanks to Dr Raffaele Califano, the outgoing Chair, for his leadership of this initiative.

As in previous years, the YO Track combines masterclasses with dedicated career development workshops to ensure that all participants improve their skills and benefit professionally from ESMO 2016. We are particularly proud of the YO Mentorship Session, which will give younger members the opportunity to discuss educational and career development needs with leading oncology experts in three areas of interest: academia; oncology practice; and the pharmaceutical industry (Monday 10 October, 09.30 – 10.30, Warsaw).

This track's programme has been carefully curated by the ESMO YO Committee with Dr Califano as Track Chair and this year, includes new Brunch Sessions (11.00 – 12.00, Saturday 8, Sunday 9 and Monday 10 October, Lisbon). Topics include: the EMA approval process for anticancer drugs; improving your literature searches; and the features of a good review article.

Other YO development opportunities include:

- **The Vesalius Talk (Sunday 9 October, 17.30 – 18.45, Bern).** A talk combined with a networking session to build collaborations between basic scientists and medical oncologists.
- **The YO Forum (Monday 10 October, 16.00 – 17.30, Lisbon).** Focus on communications skills and leadership techniques.



Matthias Preusser: Chair of the ESMO Young Oncologists Committee

Immunotherapy continues to be a major theme among the accepted abstracts at ESMO 2016, and with this in mind, the YO Masterclass (Sunday 9 October, 14.15 – 17.15, Bern) focuses on 'Harnessing the immune system for cancer therapy'. This session will precis the current hot topics in immunology with a view to enhancing your expertise in this area.



For full details of the YO Track go to

www.esmo.org/Conferences/ESMO-2016-Congress/Programme/Young-Oncologists-Track

Finally, please take note of the **Fellowship Session at 14.15 – 15.45 in Lisbon** on Monday 10 October when this year's awardees will be announced and two previous fellows will present their projects. One of last year's fellows, Dr Angela Lamarca from The Christie NHS Foundation Trust, Manchester, UK enthused, "The ESMO Translational Fellowship has provided a life-changing opportunity for me both personally and for my medical career. It has given me the opportunity to learn from colleagues who are considered to be international leads in the treatment of patients with hepato-pancreaticobiliary and neuroendocrine tumours, and to launch my career as a clinical and translational researcher." We hope that you will join us to celebrate the achievements of these exceptional YOs.

The Young Oncologists Track aims to improve skills, facilitate professional development and encourage collaboration across a network of practising and research oncologists.

ESMO/ASCO Global Curriculum in Medical Oncology Edition 2016 published



Recently published in ESMO's new open access journal *ESMO Open*, the ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 is a set of guidelines on medical oncologist training

developed by the joint ESMO/ASCO Global Curriculum Working Group and officially endorsed by 47 oncology societies from 44 countries worldwide. Chair of the ESMO/ASCO Global Curriculum Working Group, Dr Christian Dittrich (Vienna, Austria), noted that, "The Global Curriculum has a tremendous impact on the education of medical oncologists. It is the basis for harmonised training."

Key updates in the 2016 edition include:

- **Stand-alone chapters/section:** immunotherapy; biological therapy; pathology; molecular pathology; laboratory medicine; translational research; genetic counselling.
- **New chapters/(sub)sections:** Principles of personalised cancer medicine; Molecular imaging; Rare cancers; Cancer treatment in patients with comorbidities; Survivorship.

- **Expanded (sub)chapters:** Targeted therapies are integrated into the (sub)chapters of the separate tumour entities wherever suitable.

Dr Rossana Berardi, member of the ESMO/ASCO Global Curriculum Working Group, and Professor Ulrik Lassen, President of the Danish Society of Clinical Oncology (DSKO) will share their perspectives on the relevance of the Global Curriculum to those responsible for the education of trainees, trainees themselves and for standardisation of training at the country level.

Learn more, attend the ESMO Focus Talk 'Setting the standards in medical oncology training: the 2016 edition of the ESMO/ASCO Global Curriculum – meet with Rossana Berardi and Ulrik Lassen on Sunday 9 October (10.45, ESMO Booth in the Society Village).

The ESMO/ASCO Global Curriculum is regarded as a fundamental reference for internationally recognised standards in medical oncology training and could help enable patients worldwide to receive state-of-the-art cancer care.

The 2016 edition of the ESMO/ASCO Global Curriculum in Medical Oncology is now available from the ESMO Booth and will also be distributed at the Focus Talk.



An accompanying video can be viewed at:

<https://www.youtube.com/watch?v=kiCvRdR9ow>



YOUR KEY TO ACCESS ESMO'S EVENTS

The ESMO Events App



Plan your event in advance with the ESMO Events App:

- Browse the programme by day and topic
- Create your own event agenda
- Stay up-to-date with the latest news
- Access the interactive exhibition map




esmo.org

BE THE FACE
on the cover of ESMO's new digital magazine!

VISIT THE ESMO BOOTH - TAKE A PHOTO TO ENTER

ESMO Focus Talks: What can ESMO do for you?

Brand new for ESMO 2016 are the ESMO Focus Talks; a series of informal exchanges between experts and the oncology community to help you discover how to make the most of what ESMO has on offer.

Held in a relaxed setting of the ESMO Booth in the Society Village, the talks are designed to appeal to delegates across the community and are expected to generate a great deal of interaction between the host and delegates. Experts will discuss their personal experiences in a variety of areas, including the use of the ESMO Biomarker Factsheets available from OncologyPRO, the importance of collaboration between researchers and oncologists, and support for oncology training and career development. Delegates are encouraged to share their questions and perspectives.

Come to the ESMO Focus Talks and find out how to make ESMO work for you.



ESMO Focus Talks

Friday 7 October, 15.30

Dr Teresa Troiani (Italy) and Dr Nicola Normanno (Italy)

Successfully validate targeted therapies: ESMO Biomarker Factsheets on OncologyPRO

Saturday 8 October, 12.30

Professor Alberto Sobrero (Italy) and Professor Carlos Caldas (UK)

Integrating science into oncology for better patient outcomes: the need for collaboration between researchers and oncologists

Sunday 9 October, 10.45

Professor Rossana Berardi (Italy) and Professor Ulrik Lassen (Denmark)

Setting standards in medical oncology training: the 2016 edition of the ESMO/ASCO Global Curriculum

Monday 10 October, 12.30

Dr Erika Martinelli (Italy) and Antonio D'Alessio (Italy)

Your career in oncology, with ESMO by your side

3 FOR 2

ESMO MEMBERSHIP OFFER

3 YEARS FOR THE PRICE OF 2!
Visit us at the ESMO Booth #1 to learn more.

esmo.org



Meet the Editor Sessions

Don't miss these Sessions: a unique opportunity to go straight to the top for answers to the questions you want to ask. This exciting initiative gives delegates the opportunity to find out what goes on behind the scenes of the ESMO journals, and to put their queries to the editors.

Sunday 9 October, 12.00

ESMO Open: Professor Christoph Zielinski



All sessions will take place at the ESMO Booth in the Society Village.

abbvie

STRIVING TO OUTSMART CANCER. TOGETHER.

At AbbVie, we build bonds with oncologists, patients, payers, advocacy groups, health authorities, and other pharmaceutical companies, because we know that advancing the science of this devastating disease is not something that one person, or even one company, can do alone.

Together we can conduct research that deepens our understanding of the disease and its pathways, to ultimately develop new molecules that make a transformational improvement in cancer care.

LEARN MORE ABOUT THE BONDS WE'RE BUILDING AT BOOTH 316.

VISIT US AT THE ESMO BOOTH

in the Society Village

BE THE FACE OF OUR NEW DIGITAL MAGAZINE

ESMO is launching a new digital magazine - sharing the lives, ideas and stories behind all that we do and showing ESMO as you have never seen us before! Fancy yourself on its cover? Get down to the ESMO booth, take a picture, and maybe see yourself on our first edition!

ESMO FOCUS TALKS

Are you looking for a practical tool to validate your therapeutic decisions? Would you like to know more about ESMO's 360° educational offer? How about a closer collaboration between oncologists and basic researchers? This and much more discussed by leading experts in an informal setting. Discover topics, speakers and schedule at the ESMO Booth.

ANNALS OF ONCOLOGY AND ESMO OPEN

Discover more about ESMO's scientific and educational journals covering all areas of oncology research and practice: our staff will be happy to guide you through the different platforms and answer all your questions here.

CLINICAL PRACTICE GUIDELINES

Pick up your free copy of the 2016 ESMO Clinical Practice Guidelines Supplement and ask for a demo of the ESMO Interactive Guidelines App.

ESMO APPS

Learn how to best use the ESMO Events App and the ESMO Interactive Guidelines App from this giant tablet.

EVENT CORNER

Discover the wealth of educational and scientific meetings ESMO is offering to keep oncologists updated and ahead of developments in cancer research and practice.

ESMO 2017: REGISTER NOW AND SAVE!

Register at the ESMO Booth to get up to 70% off the full fee or try your luck wearing your ESMO 2017 scarf to win a free registration. Discover all the details here!

EPOSTERS USB

Present your voucher and get your free USB with ePosters from ESMO 2016.

ONCOLOGYPRO

Biomarkers factsheets, Clinical trials resources, webcasts... Discover more about ESMO's educational portal for oncologists.

EDUCATION

From medical students to experienced oncologists, ESMO education offers something for everyone.

PUBLICATIONS

Essentials for Clinicians series, Handbooks and many other books... ESMO publications are delivered by a multidisciplinary faculty of over 300 experts and cover a variety of cancer-related areas. Learn about current and future products, available at the ESMO Booth.

JOIN ESMO


Take advantage of the 3 x 2 onsite offer: renew or become an ESMO Member now!

MEMBERSHIP SERVICES

Renew your membership, update your records, join ESMO... our staff is happy to assist you!

YOUNG ONCOLOGISTS CORNER

Educational courses, fellowships, workshops and lots of networking opportunities: to refine your skills, gain access to the latest developments and keep in touch with colleagues from around the world. Discover all ESMO YO initiatives here.



esmo.org

ESMO 2017: You can't afford to miss it!



2017

MADRID SPAIN
8-12 SEPTEMBER 2017
IN PARTNERSHIP WITH EACR



2018

MUNICH GERMANY
19-23 OCTOBER 2018

STAY TUNED!

2019

ESMO IS ANNUAL!

Mark your calendar for the upcoming ESMO Congresses.

Under the slogan, 'Integrating science into oncology for better patient outcomes', ESMO 2017 is being held in partnership with the European Association for Cancer Research (EACR) to bring clinicians and scientists together to ask the questions that matter to cancer patients.

"This will be the first time the annual ESMO Congress is held with EACR and the collaboration will make ESMO 2017 a truly integrated congress, which will focus on advancing oncology and improving treatment options for patients," believes ESMO President, Professor Fortunato Ciardiello.

You can get further insight into why strengthening collaboration between researchers and clinicians is so crucial for the future of oncology by coming to tomorrow's **ESMO Focus Talk (12.30 – 13.00, ESMO Booth)**, where ESMO 2016 awardees, Professor Alberto Sobrero and Professor Carlos Caldas, will reveal how exchange between researchers and oncologists has benefited their work. The Talk will also give you the chance to share your experiences and perspectives with experts and colleagues.

Join Professors Alberto Sobrero and Carlos Caldas to discuss the importance of researcher–oncologist collaboration: ESMO Focus Talk; tomorrow, 12.30 – 13.00, ESMO Booth.



Save on ESMO 2017 registration by visiting the ESMO Booth in the Society Village today

ESMO offers you two fantastic opportunities to get reduced, or even free, registration for the ESMO 2017 Congress.

Register for ESMO 2017 today and save up to 70%!

This incredible offer is open to the first 100 people who register for ESMO 2017 while onsite in Copenhagen.

You'll have to hurry if you don't want to miss out!

ESMO members will benefit from the most discounted registration rates. So if you're not already a member, why not join today for the chance to make the most of this offer and all the other benefits of membership.

Take a selfie to win free ESMO 2017 registration!

Show us how you wear your ESMO 2017 scarf and you could win free registration for ESMO 2017.

It's as easy as 1, 2, 3:

- 1 Collect your ESMO 2017 scarf from the ESMO Booth
- 2 Take a selfie of you wearing it—if you need inspiration, look at the '10 ways to wear your scarf' video at youtube.com/ESMOchannel
- 3 Send your picture to us via: Twitter, with the hashtag #ESMO17 or email, communication@esmo.org



Selfies will be entered into a draw and a winner will be chosen at random.

For mCRPC patients with bone metastases

Introduce Xofigo® for patients progressing on first-line therapy^{1,2}

LIFE.

JUST GOT LONGER.

EXTEND MEDIAN OVERALL SURVIVAL TO 14.9 MONTHS^{3a}



Essential Information

Xofigo 1100 kBq/mL solution for injection (Refer to full Summary of Product Characteristics before prescribing).

Composition¹: Active ingredient: radium Ra 223 dichloride (radium-223 dichloride, 1100 kBq/mL, corresponding to 0.58 ng radium-223 at the reference date). Each vial contains 6 mL of solution (6.6 MBq radium-223 dichloride at the reference date). Excipients¹: Water for injections, sodium citrate, sodium chloride, hydrochloric acid, dilute.

Indication: Treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo should be administered only by persons authorised to handle radiopharmaceuticals in designated clinical settings.

Contraindications: There are no known contraindications.

Warnings and Precautions: Bone marrow suppression, notably thrombocytopenia, neutropenia, leukopenia and pancytopenia, has been reported. Haematological evaluation of patients must be performed at baseline and prior to every dose. In case there is no recovery in values for

absolute neutrophil count (ANC) and haemoglobin within 6 weeks after the last administration of Xofigo despite receiving standard of care, further treatment with Xofigo should only be continued after careful benefit/risk evaluation. Patients with evidence of compromised bone marrow reserve e.g. following prior cytotoxic chemotherapy and/or radiation treatment (EBRT) or patients with advanced diffuse infiltration of the bone (EOD4; "superscan"), should be treated with caution as an increased incidence of haematological adverse reactions such as neutropenia and thrombocytopenia has been observed. Limited available data indicate that patients receiving chemotherapy after Xofigo had a similar haematological profile compared to patients receiving chemotherapy after placebo. Crohn's disease and ulcerative colitis: due to the faecal excretion of Xofigo, radiation may lead to aggravation of acute inflammatory bowel disease, therefore Xofigo should only be administered to these patients after a careful benefit-risk assessment. In patients with untreated imminent or established spinal cord compression, treatment with standard of care, as clinically indicated, should be completed before starting or resuming treatment with Xofigo. In patients with bone fractures, orthopaedic

stabilisation of fractures should be performed before starting or resuming treatment with Xofigo. In patients treated with bisphosphonates and Xofigo, an increased risk of development of osteonecrosis of the jaw (ONJ) cannot be excluded. In the phase III study, cases of ONJ have been reported in 0.67% patients (4/600) in the Xofigo arm compared to 0.33% patients (1/301) in the placebo arm. However, all patients with ONJ were also exposed to prior or concomitant bisphosphonates and prior chemotherapy. Xofigo contributes to a patient's overall long-term cumulative radiation exposure and therefore may be associated with an increased risk of cancer and hereditary defects. No cases of Xofigo-induced cancer have been reported in clinical trials in follow-up of up to three years. Depending on the volume administered, this medicinal product can contain up to 2.35 mmol (54 mg) sodium per dose.

Undesirable effects: Very common: thrombocytopenia, diarrhoea, vomiting, nausea; Common: neutropenia, pancytopenia, leukopenia,

injection site reactions; Uncommon: lymphopenia.

Classification for supply: Medicinal product subject to restricted medical prescription.

Marketing Authorisation Holder: Bayer Pharma AG, 13342 Berlin, Germany.

Date of revision of the underlying Prescribing Information: April 2016.

¹List of excipients should only be included when required according to national legislation.

mCRPC=metastatic castration-resistant prostate cancer.

³Updated analysis from ALSYMPCA.

References: 1. Mohler JL, Armstrong AJ, Bahnson RR, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Prostate Cancer, Version 3.2016. National Comprehensive Cancer Network; 2016:1-108. 2. Mottet N, Bellmunt J, Briers E, et al. Guidelines on Prostate Cancer. European Association of Urology; 2015:1-156. 3. Xofigo® (radium Ra 223 dichloride) solution for injection Summary of Product Characteristics (SmPC), Bayer Pharma AG, 13342 Berlin, Germany, 2016.



© 2016 Bayer Pharma AG. April 2016.
G.MKT.SM.ON.04.2016.1609

Learn more about Xofigo at www.xofigo.com/hcp

ESMO 2016 programme: A collective effort deserves a collective thanks


ESMO President Professor Fortunato Ciardiello and ESMO 2016 Scientific Chair Professor Andrés Cervantes wish to convey their gratitude to the ESMO 2016 Scientific Committee for working tirelessly to put together such an excellent scientific and educational programme. Through a huge collaborative effort this international, multidisciplinary event is able to offer something for everybody.

This year we received an exceptionally large volume of new data, highlighting novel treatment approaches and long-awaited results. Overall, 1,639 abstracts were accepted, including 47 late-breaking abstracts and several practice-changing studies addressing unmet

medical needs. The scientific programme alone includes more than 20 tracks, with multiple sessions per track, each featuring several presentations and discussion sessions.

As always, the focus is on innovation and knowledge that will ultimately provide patients with effective treatment options and optimal care. "As the leading oncology event in Europe, the ESMO 2016 Congress gives oncologists the chance to learn about the latest findings in the most in-demand fields of oncology, such as targeted therapies and immunotherapies, and to engage with colleagues from across the oncology specialities," commented Professor Cervantes.

The ESMO 2016 Scientific Committee deserves a special thank you for selecting content for such a comprehensive, relevant and high quality programme.



Basic science and translational research: Richard Marais, Manchester, UK; *Breast cancer, early stage:* Marco Colleoni, Milan, Italy; *Breast cancer, metastatic:* Robert E. Coleman, Sheffield, UK; *CNS tumours:* Alba Brandes, Bologna, Italy; *Developmental therapeutics:* Jordi Rodón, Barcelona, Spain; *Gastrointestinal tumours, colorectal:* Julien Taieb, Paris, France; *Gastrointestinal tumours, non-colorectal:* Florian Lordick, Leipzig, Germany; *Genitourinary tumours, prostate:* Gerhardt Attard, Sutton, UK; *Genitourinary tumours, non-prostate:* Joaquim Bellmunt, Boston, MA, USA; *Gynaecological cancers:* Sandro Pignata, Naples, Italy; *Haematological malignancies:* Christian Buske, Ulm, Germany; *Head and neck cancer:* Amanda Psyrri, Athens, Greece; *Immunotherapy of cancer:* John B. Haanen, Amsterdam, Netherlands; *Melanoma and other skin tumours:* Olivier Michielin, Lausanne, Switzerland; *NETs and endocrine tumours:* Rocio Garcia-Carbonero, Madrid, Spain; *Non-metastatic NSCLC and other thoracic malignancies:* Dirk De Ruyscher, Maastricht, Netherlands; *NSCLC, metastatic:* Egbert Smit, Amsterdam, Netherlands; *Public health and health economics:* Rosa Giuliani, Rome, Italy; *Sarcoma:* Olivier Mir, Villejuif, France; *Supportive and palliative care:* Karin Jordan, Halle, Germany

Hot topics at ESMO 2016



Andrés Cervantes:
ESMO 2016 Scientific Chair

It is a real privilege to be the ESMO 2016 Scientific Chair—and a big responsibility, especially in a year in which the congress received an unprecedented number of high-quality abstracts from both within and outside Europe. What is perhaps even more exciting is that a good number of these abstracts, more than at any previous ESMO

Congress, feature potentially practice-changing results. As such, delegates can expect to learn about data on important treatment innovations in a variety of high-incidence tumours, including non-small-cell lung cancer, breast cancer and prostate cancer, and those for which results have been long awaited, including ovarian cancer, stage 3 melanoma and head and neck cancer.

1,639 abstracts, including 47 late-breaking abstracts, were accepted at ESMO 2016.

The programme represents a huge collaborative effort on the part of the Scientific Committee and after months of hard work I am confident that we have prepared an exciting and varied scientific programme supporting the congress tagline, 'From disease treatment to patient care'. As might be expected, targeted therapy is a central feature. A record number of abstracts on biomarkers were submitted, underlining the importance of patient selection in treatment efficacy. Immunotherapy appears widely throughout the programme and a fully dedicated Onco-immunology Track focuses on patient selection for treatment and the management of side effects.

What if you could give her more progression-free time?

Diagnosis of metastatic cancer

Disease progression

© 2016 Pfizer Pharma GmbH PP-IBR-DNK-0014. Date of preparation: July 2016

The ESMO awards: Celebrating outstanding oncologists

Come to see four truly exceptional oncologists receive their ESMO awards! Three oncologists will be awarded in today's **Opening Session (12.00 – 13.20, Copenhagen)**, and the fourth on Sunday in the **Women for Oncology Session (9.00 – 10.30, Bern)**.

The **ESMO Award** is given to a member in recognition of their outstanding contribution to medical oncology. This year's recipient, Professor Alberto Sobrero of the IRCCS San Martino IST, Genova, Italy, is a world-renowned expert in gastrointestinal cancers. He is being honoured for his tireless and original work and innumerable publications in this field as well as his ongoing collaborations and prominence within the ESMO community. Professor Sobrero is the Chair of the ESMO 2017 Congress, a member of the ESMO Educational Committee, and also the ESMO Faculty Co-ordinator for Gastrointestinal Tumours.



"One always wonders if one is doing well in professional life: the ESMO award is certainly the best answer to this questioning."

Professor Alberto Sobrero

The **ESMO Lifetime Achievement Award** recognises extraordinary dedication to cancer research and education. This year this accolade goes to Professor Sir Richard Peto of the University of Oxford's Nuffield Department of Population Health, UK. Sir Peto is the founder of the Early Breast Cancer Trialists Collaborative Group (EBCTCG), which has been responsible for extensive improvements in the management of early breast cancer and a major influence in the ongoing evolution of clinical trial strategies in this area. Sir Peto was also in the vanguard of oncologists describing the hazards of tobacco smoking and the likely worldwide burdens of current smoking patterns.



"This award recognises not just me, but the Early Breast Cancer Trialists' Collaborative Group as a whole, including the patients and staff in hundreds of randomised trials."

Professor Sir Richard Peto

The **Hamilton Fairley Award** recognises outstanding achievements in cancer science and clinical/translational research and this year, following a unanimous decision, it is being presented to Professor Carlos Caldas of the Cancer Research UK Cambridge Institute, University of Cambridge, UK. The prolific and ground-breaking work of Professor Caldas' team in breast cancer includes redefinition of its taxonomy, identification of novel immune response modulators and monitoring biomarkers, and the development of model systems and biopsy techniques.



"ESMO is the association representing medical oncologists in Europe...this is an extremely prestigious award...(and) it is a recognition of excellence and of the contributions my group has made to our understanding of breast cancer."

Professor Carlos Caldas

The **ESMO Women for Oncology Award** goes to Professor Sumitra Thongprasert of the Chiang Mai University, Thailand, in recognition of her distinguished career and in praise of her work as a role model for women in oncology. Professor Thongprasert's achievements are extensive, including a directorship of the International Association for the Study of Lung Cancer, member of the ESMO Developing Country Task Force and a founder member of the Thai Society for Clinical Oncology. While undertaking all of these roles, Professor Thongprasert has been a passionate advocate for female participation and leadership in the oncology workforce.



"The award is further impetus to strive towards contributing something meaningful to ESMO and especially to women oncologists."

Professor Sumitra Thongprasert

Many congratulations to all of our inspirational award winners!



oncology//PRO
Educational Portal for Oncologists

Learn how Biomarker Factsheets can **assist you in your daily practice**

The ESMO educational portal for oncologists, 'OncologyPRO,' features a series of factsheets on validated biomarkers across a range of solid tumours. Developed by the ESMO Translational Research and Personalised Medicine Working Group, 14 factsheets are currently available with more coming soon (take a look at oncologypro.esmo.org/Science-Education/Factsheets-on-Biomarkers).

Learn more about how you can leverage the ESMO Factsheets on Biomarkers to validate your choice for targeted therapies at the ESMO Focus Talk today (15.30 – 16.00, ESMO Booth in the Society Village). Two of the Factsheet authors who are actively involved in translational research, Dr Nicola Normanno (INT-Fondazione Pascale, Napoli, Italy) and Dr Teresa Troiani (Seconda Università di Napoli, Italy) will explain more about how the Factsheets can be used to support multidisciplinary work between (molecular) pathologists and medical oncologists for improved patient outcomes.

Don't miss this opportunity for learning and information exchange with key experts in oncology! The ESMO Focus Talk schedule is available at the ESMO Booth in the Society Village.

The ESMO Focus Talk is a brand-new initiative that will be launched at ESMO 2016: esteemed oncology experts and thought leaders will meet congress attendees in a dedicated area of the ESMO Booth to talk about topics of interest to the oncology community in an informal setting. Oncology experts will share their professional and personal experiences, while asking for feedback and comments from attendees.

Dr Troiani explained that, "As targeted therapies are increasingly used in oncology, the identification and validation of biomarkers is of paramount importance. Biomarkers enable pharmacological responses to be evaluated objectively and, by providing information on tumours most likely to respond to a specific treatment, can help to guide personalised therapy."

"The Factsheets not only provide comprehensive information on cancer biomarkers, but they also provide a practical insight into their application in clinical practice," added Dr Normanno.

COPENHAGEN 2016 **ESMO** congress

The ESMO Colloquium Immuno-Oncology in Pole Position is provided by ESMO and supported by Roche

ESMO COLLOQUIA

IMMUNO-ONCOLOGY IN POLE POSITION

FRIDAY, 7 OCTOBER 2016 COPENHAGEN DENMARK
18:00-19:30 ROOM: BRUSSELS

For more information please see the online programme

! ESMO Magnitude of Clinical Benefit Scale

The ESMO-MCBS offers a rational, structured and consistent approach to stratifying a drug's clinically meaningful benefit. For more information on the ESMO-MCBS, including how to use it, don't miss Sunday's Special Session,

'Clinical benefit of cancer drugs'; 14.45 – 16.15, Helsinki.



Remember to collect your electronic poster **USB** from the **ESMO Booth**.

NOW
APPROVED
in Squamous
NSCLC

GIOTRIF®

Proven efficacy vs
gefitinib (PFS and TTF)
and vs chemotherapy in
1st-line EGFR M+ NSCLC^{1-4*}



* LUX-Lung 3 (vs pemetrexed/cisplatin) and LUX-Lung 6 (vs gemcitabine/cisplatin): superior PFS (primary endpoint) and superior OS in Del19 subgroup (secondary endpoint); LUX-Lung 7 (vs gefitinib): superior PFS (co-primary endpoint).

GIOTRIF® Abbreviated European Prescribing Information. Please refer to local prescribing information as it may vary between countries. Different brand names are used in some countries. Presentations: Film-coated tablets each containing 20 mg, 30 mg, 40 mg or 50 mg afatinib (as dimaleate). Indication: Giotrif® as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. Posology and method of administration: EGFR mutation status should be established prior to initiation of Giotrif®. Recommended dose is 40 mg oral once daily to be taken without food. Dose escalation to a maximum of 50 mg/day may be considered in patients who tolerate 40 mg/day. Symptomatic adverse reactions may be successfully managed by treatment interruption and dose reductions or treatment discontinuation. No starting dose adjustment necessary in patients with mild or moderate renal or hepatic impairment. Not recommended in patients with severely impaired renal function (< 30 mL/min creatinine clearance), severe hepatic impairment, children or adolescents. Contraindications: Hypersensitivity to afatinib or to any of its excipients. Special warnings and precautions for use: Diarrhoea, including severe diarrhoea, and rash/acne may require interruption and dose reduction or discontinuation of therapy. Higher exposure to afatinib has been observed in female patients, patients with lower body weight and those with underlying renal impairment. Interstitial Lung Disease (ILD) or ILD-like adverse reactions, including fatalities, have been reported in patients receiving Giotrif®. If ILD is diagnosed, permanently discontinue Giotrif®. Discontinue Giotrif® in patients who develop severe hepatic impairment. If keratitis is diagnosed, the benefits and risks of continuing treatment should be carefully considered. Cardiac monitoring, including an LVEF assessment, should be considered in patients with cardiac risk factors and patients who develop relevant cardiac signs/symptoms during treatment. Giotrif® contains lactose. Interactions: P-gp inhibitors should be administered using staggered dosing, preferably 6 hours or 12 hours apart from Giotrif®. Strong inducers of P-gp may decrease exposure to afatinib. It is unlikely that Giotrif® changes the plasma concentrations of other P-gp substrates. Giotrif® may increase the bioavailability of orally administered breast cancer resistance protein (BCRP) substrates. Fertility, pregnancy and lactation: Women of childbearing potential should be advised to avoid becoming pregnant. No or limited amount of data are available from use in pregnant women. The risk for humans is thus unknown. Advise against breast-feeding while receiving Giotrif®. An adverse effect on fertility cannot be excluded. Effects on ability to drive and use machines: Minor influence. Undesirable effects: Very common: diarrhoea, rash, dermatitis acneiform, pruritus, dry skin, epistaxis, decreased appetite, paronychia. Common: cystitis, dehydration, hypokalaemia, dysgeusia, conjunctivitis, dry eye, rhinorrhoea, dyspepsia, cheilitis, alanine aminotransferase increased, aspartate aminotransferase increased, palmarplantar erythrodysesthesia syndrome, muscle spasms, renal impairment/renal failure, pyrexia, weight decreased. Uncommon: keratitis, interstitial lung disease. Liver function test abnormalities including elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were observed. Overdose: dermatological (rash/ acne) and gastrointestinal events (especially diarrhoea). Marketing Authorisation Number(s): EU/1/13/879/001 to EU/1/13/879/012. Marketing Authorisation Holder: Boehringer Ingelheim International GmbH, Binger Strasse 173, D-55216 Ingelheim am Rhein, Germany. Date of last revision of prescribing information: 24/05/2016.

Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name Giotrif® and in the US under the brand name Giotrif®. In Europe it is approved for: 1) the treatment of epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); 2) locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. Registration conditions differ internationally, please refer to locally approved prescribing information. Afatinib is under regulatory review by health authorities in other countries worldwide. Afatinib is not approved in other indications. The compulsory product information is freely available at the booth.

EGFR M+=epidermal growth factor receptor mutation positive; NSCLC=non-small cell lung cancer; PFS=progression-free survival; OS=overall survival; TTF=time to treatment failure.

1. Yang JC et al. Lancet Oncol. 2015;16(2):141-51.
2. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
3. Wu YL et al. Lancet Oncol. 2014;15(2):213-22.
4. Park K et al. Lancet Oncol. 2016;17(5):577-89.

LET'S WORK
ONCOLOGY FROM BOEHRINGER INGELHEIM

 **Boehringer
Ingelheim**

 **GIOTRIF®**
(afatinib) tablets
RAISING EXPECTATIONS